Epion Therapeutics
Burlington
About Epion Therapeutics
Epion is developing a minimally invasive treatment for an ectatic corneal disease that can bring early intervention to millions of patients globally. Their EpiSmart approach is a transformative cross-linking system designed to treat keratoconus without disrupting the epithelium, allowing for a rapid return to normal activities. Epion was founded and is supported by experts in the field, including Michael W. Belin, MD, Chief Medical Officer, who developed the Belin ABCD Progression Display, which is able to identify keratoconus progression earlier than previously relied upon metrics.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $32.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2022)
- Website: epiontx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science, Personal Health, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/epion-therapeutics-84114 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.